{"id":906209,"date":"2025-11-05T18:19:46","date_gmt":"2025-11-05T23:19:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/"},"modified":"2025-11-05T18:19:46","modified_gmt":"2025-11-05T23:19:46","slug":"form-8-1a-b-avadel-pharmaceuticals-plc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/","title":{"rendered":"FORM 8.1(a) & (b) – Avadel Pharmaceuticals plc"},"content":{"rendered":"
\n

U.K. DISCLOSURE, Nov. 05, 2025 (GLOBE NEWSWIRE) — <\/p>\n

\n Ap9<\/strong>\n <\/p>\n

\n FORM 8.1(a) & (b)<\/strong>
\n
\n (Opening Position Disclosure)<\/strong>\n <\/p>\n

\n IRISH TAKEOVER PANEL<\/strong>\n <\/p>\n

\n OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE<\/strong>\n <\/p>\n

\n 1.<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0KEY INFORMATION<\/strong><\/p>\n\n\n\n\n\n\n\n
\n (a) <\/strong>
\n Full name of discloser:<\/strong>\n <\/td>\n		Avadel Pharmaceuticals plc<\/td>\n<\/tr>\n
\n (b) <\/strong>
\n Owner or controller of interests and short <\/strong>
\n positions disclosed, if different from 1(a):<\/strong><\/p>\n

The naming of nominee or vehicle companies is <\/em>
\n insufficient. For a trust, the trustee(s), settlor and <\/em>
\n beneficiaries must be named.<\/em>\n <\/td>\n

N\/A<\/td>\n<\/tr>\n
\n (c) <\/strong>
\n Name of offeror\/offeree in relation to whose <\/strong>
\n relevant securities this form relates:<\/strong><\/p>\n

Use a separate form for each offeror\/offeree<\/em>\n <\/td>\n

Avadel Pharmaceuticals plc<\/td>\n<\/tr>\n
\n (d) <\/strong>
\n Is the discloser the offeror or the offeree?<\/strong>\n <\/td>\n		\n OFFEREE<\/strong>\n <\/td>\n<\/tr>\n
\n (e) <\/strong>
\n Date position held:<\/strong><\/p>\n

The latest practicable date prior to the disclosure<\/em>\n <\/td>\n

4 November 2025<\/td>\n<\/tr>\n
\n (f) <\/strong>
\n In addition to the company in 1(c) above, is the <\/strong>
\n discloser also making disclosures in respect <\/strong>
\n of any other party to the offer?<\/strong><\/p>\n

If it is a cash offer or possible cash offer, state <\/em>
\n \u201cN\/A\u201d<\/em>\n <\/td>\n

N\/A<\/td>\n<\/tr>\n<\/table>\n

\n
\n
2.<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0INTERESTS AND SHORT POSITIONS<\/strong><\/p>\n

\n If there are interests and positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.<\/em>\n <\/p>\n

\n Ap10<\/strong>\n <\/p>\n

\n Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates <\/strong>(Note 1)<\/p>\n\n\n\n\n\n\n\n\n
\n Class of relevant security: <\/strong>(Note 2)<\/td>\n<\/tr>\n
\u00a0<\/td>\n\n Interests<\/strong>\n <\/td>\n\n Short positions<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\n Number<\/strong>\n <\/td>\n\n %<\/strong>\n <\/td>\n\n Number<\/strong>\n <\/td>\n\n %<\/strong>\n <\/td>\n<\/tr>\n
\n (1)<\/strong>\u00a0\u00a0\u00a0Relevant securities owned<\/strong>and\/or controlled:<\/strong><\/td>\nNIL<\/td>\n–<\/td>\nNIL<\/td>\n–<\/td>\n<\/tr>\n
\n (2)<\/strong>\u00a0\u00a0\u00a0Cash-settled derivatives:<\/strong><\/td>\nNIL<\/td>\n–<\/td>\nNIL<\/td>\n–<\/td>\n<\/tr>\n
\n (3)<\/strong>\u00a0\u00a0\u00a0Stock-settled derivatives<\/strong>(including options) and<\/strong>agreements to purchase\/<\/strong>sell:<\/strong><\/td>\nNIL<\/td>\n–<\/td>\nNIL<\/td>\n–<\/td>\n<\/tr>\n
\n Total:<\/strong>\n <\/td>\nNIL<\/td>\n–<\/td>\nNIL<\/td>\n–<\/td>\n<\/tr>\n<\/table>\n

\n
\n
All interests and all short positions should be disclosed.<\/em>\n <\/p>\n

\n Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form\u00a08.<\/em>\n <\/p>\n

\n 3.<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0INTERESTS AND SHORT POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY MAKING THE DISCLOSURE<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\n Details of any interests and short positions (including directors\u2019<\/strong>
\n and other employee options) of any person acting in concert with<\/strong>
\n the party making the disclosure: <\/strong>\n <\/td>\n<\/tr>\n
The directors of the Offeree detailed in the table below (together with their connected persons under Rule 3.3(b)(ii) of Part A of the Irish Takeover Rules) have the following interests in the Offeree:<\/td>\n<\/tr>\n
Director<\/td>\nClass of Relevant Security<\/td>\nNumber of ordinary shares held at midnight on 4 November 2025<\/td>\nPercentage of total issued ordinary share capital (rounded) (%)<\/td>\nTotal number of ordinary shares underlying outstanding stock options, restricted share units and other subscription rights<\/td>\n<\/tr>\n
Peter Thornton<\/td>\nOrdinary shares of US$0.01 each<\/td>\n104,055<\/td>\n0.11<\/td>\n252,000<\/td>\n<\/tr>\n
Linda Palczuk<\/td>\nOrdinary shares of US$0.01 each<\/td>\n67,900<\/td>\n0.07<\/td>\n277,000<\/td>\n<\/tr>\n
Geoffrey Glass<\/td>\nOrdinary shares of US$0.01 each<\/td>\n155,979<\/td>\n0.16<\/td>\n252,000<\/td>\n<\/tr>\n
Eric Ende<\/td>\nOrdinary shares of US$0.01 each<\/td>\n208,900<\/td>\n0.21<\/td>\n260,057<\/td>\n<\/tr>\n
Gregory Divis<\/td>\nOrdinary shares of US$0.01 each<\/td>\n169,100<\/td>\n0.17<\/td>\n2,922,000<\/td>\n<\/tr>\n
Mark McCamish<\/td>\nOrdinary shares of US$0.01 each<\/td>\n78,025<\/td>\n0.08<\/td>\n302,000<\/td>\n<\/tr>\n
Naseem Sajjid Amin<\/td>\nOrdinary shares of US$0.01 each<\/td>\n11,000<\/td>\n0.01<\/td>\n82,500<\/td>\n<\/tr>\n
TOTAL<\/td>\n–<\/td>\n794,959<\/td>\n0.81<\/td>\n4,347,557<\/td>\n<\/tr>\n<\/table>\n

\n
\n
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.<\/em>\n <\/p>\n\n\n\n\n\n\n\n\n\n
\n Interests and short positions held by Folio Investments Inc., an entity under the same control as Goldman Sachs & Co. LLC, presumed concert party of the offeree<\/strong>\n <\/td>\n<\/tr>\n
\n Class of relevant security: <\/strong>Ordinary shares of $0.01 each<\/td>\n<\/tr>\n
\u00a0<\/td>\n\n Interests<\/strong>\n <\/td>\n\n Short positions<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\n Number<\/strong>\n <\/td>\n\n %<\/strong>\n <\/td>\n\n Number<\/strong>\n <\/td>\n\n %<\/strong>\n <\/td>\n<\/tr>\n
\n (1)<\/strong>\u00a0\u00a0\u00a0Relevant securities owned<\/strong>and\/or controlled:<\/strong><\/td>\n20<\/td>\n0.00<\/td>\n0<\/td>\n–<\/td>\n<\/tr>\n
\n (2)<\/strong>\u00a0\u00a0\u00a0Cash-settled derivatives:<\/strong><\/td>\n0<\/td>\n0.00<\/td>\n0<\/td>\n–<\/td>\n<\/tr>\n
\n (3)<\/strong>\u00a0\u00a0\u00a0Stock-settled derivatives<\/strong>(including options) and<\/strong>agreements to purchase\/<\/strong>sell:<\/strong><\/td>\n0<\/td>\n0.00<\/td>\n0<\/td>\n–<\/td>\n<\/tr>\n
\n Total:<\/strong>\n <\/td>\n20<\/td>\n0.00<\/td>\n0<\/td>\n–<\/td>\n<\/tr>\n<\/table>\n

\n Ap11<\/strong>\n <\/p>\n

\n 4.<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0OTHER INFORMATION<\/strong><\/p>\n

\n (a)<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Indemnity and other dealing arrangements<\/strong><\/p>\n\n\n\n\n\n
\n Details of any indemnity or option arrangement, or any agreement<\/strong>
\n or understanding, formal or informal, relating to relevant securities<\/strong>
\n which may be an inducement to deal or refrain from dealing<\/strong>
\n entered into by the party to the offer making the disclosure or any<\/strong>
\n person acting in concert with it:<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n
\n Irrevocable commitments and letters of intent should not be included. If<\/em>
\n there are no such agreements, arrangements or understandings, state<\/em>
\n \u201cnone\u201d<\/em>\n <\/td>\n<\/tr>\n
None <\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n
\n
(b)<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Agreements, arrangements or understandings relating to options or derivatives<\/strong><\/p>\n\n\n\n
\n Full details of any agreement, arrangement or understanding<\/strong>
\n between the person disclosing and any other person relating<\/strong>
\n to the voting rights of any relevant securities under any option<\/strong>
\n referred to on this form or relating to the voting rights or future<\/strong>
\n acquisition or disposal of any relevant securities to which any<\/strong>
\n derivative referred to on this form is referenced. If none, this<\/strong>
\n should be stated.<\/strong>\n <\/td>\n<\/tr>\n
None <\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n
\n
(c)<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Attachments<\/strong><\/p>\n\n\n\n
\n Is a Supplemental Form 8 attached?<\/strong>\n <\/td>\n\n YES\/NO<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\nNo<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n\n\n\n\n
\n Date of disclosure:<\/strong>\n <\/td>\n5 November 2025<\/td>\n<\/tr>\n
\n Contact name:<\/strong>\n <\/td>\nJerad Seurer<\/td>\n<\/tr>\n
\n Telephone number:<\/strong>\n <\/td>\n+1 636-730-1420<\/td>\n<\/tr>\n<\/table>\n

\n
\n
Public disclosures under Rule 8.1 of the Rules must be made to a Regulatory Information Service.<\/em>\n <\/p>\n

\n Ap12<\/strong>\n <\/p>\n

\n NOTES ON FORM 8.1(a) and (b)<\/em>\n <\/p>\n

\n 1.<\/em>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0See the definition of \u201cinterest in a relevant security\u201d in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) of Part B of the Rules.<\/em><\/p>\n

\n 2.<\/em>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0See the definition of \u201crelevant securities\u201d in Rule 2.1 of Part A of the Rules.<\/em><\/p>\n

\n 3.<\/em>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.<\/em><\/p>\n

\n For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.<\/em>\n <\/p>\n

\n References in these notes to \u201cthe Rules\u201d are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.<\/em>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

U.K. DISCLOSURE, Nov. 05, 2025 (GLOBE NEWSWIRE) — Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0KEY INFORMATION (a) Full name of discloser: Avadel Pharmaceuticals plc (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N\/A (c) Name of offeror\/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror\/offeree Avadel Pharmaceuticals plc (d) Is the discloser the offeror or the offeree? … <\/p>\n

Continue reading “FORM 8.1(a) & (b) – Avadel Pharmaceuticals plc”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-906209","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFORM 8.1(a) & (b) - Avadel Pharmaceuticals plc - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FORM 8.1(a) & (b) - Avadel Pharmaceuticals plc - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"U.K. DISCLOSURE, Nov. 05, 2025 (GLOBE NEWSWIRE) — Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0KEY INFORMATION (a) Full name of discloser: Avadel Pharmaceuticals plc (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N\/A (c) Name of offeror\/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror\/offeree Avadel Pharmaceuticals plc (d) Is the discloser the offeror or the offeree? … Continue reading "FORM 8.1(a) & (b) – Avadel Pharmaceuticals plc"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-05T23:19:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTUwNyM3MjQ2MzI3IzIwOTA5NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/form-8-1a-b-avadel-pharmaceuticals-plc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/form-8-1a-b-avadel-pharmaceuticals-plc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"FORM 8.1(a) & (b) – Avadel Pharmaceuticals plc\",\"datePublished\":\"2025-11-05T23:19:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/form-8-1a-b-avadel-pharmaceuticals-plc\\\/\"},\"wordCount\":916,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/form-8-1a-b-avadel-pharmaceuticals-plc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2OTUwNyM3MjQ2MzI3IzIwOTA5NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/form-8-1a-b-avadel-pharmaceuticals-plc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/form-8-1a-b-avadel-pharmaceuticals-plc\\\/\",\"name\":\"FORM 8.1(a) & (b) - Avadel Pharmaceuticals plc - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/form-8-1a-b-avadel-pharmaceuticals-plc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/form-8-1a-b-avadel-pharmaceuticals-plc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2OTUwNyM3MjQ2MzI3IzIwOTA5NTM=\",\"datePublished\":\"2025-11-05T23:19:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/form-8-1a-b-avadel-pharmaceuticals-plc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/form-8-1a-b-avadel-pharmaceuticals-plc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/form-8-1a-b-avadel-pharmaceuticals-plc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2OTUwNyM3MjQ2MzI3IzIwOTA5NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2OTUwNyM3MjQ2MzI3IzIwOTA5NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/form-8-1a-b-avadel-pharmaceuticals-plc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FORM 8.1(a) & (b) – Avadel Pharmaceuticals plc\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FORM 8.1(a) & (b) - Avadel Pharmaceuticals plc - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/","og_locale":"en_US","og_type":"article","og_title":"FORM 8.1(a) & (b) - Avadel Pharmaceuticals plc - Market Newsdesk","og_description":"U.K. DISCLOSURE, Nov. 05, 2025 (GLOBE NEWSWIRE) — Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0KEY INFORMATION (a) Full name of discloser: Avadel Pharmaceuticals plc (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N\/A (c) Name of offeror\/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror\/offeree Avadel Pharmaceuticals plc (d) Is the discloser the offeror or the offeree? … Continue reading \"FORM 8.1(a) & (b) – Avadel Pharmaceuticals plc\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-05T23:19:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTUwNyM3MjQ2MzI3IzIwOTA5NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"FORM 8.1(a) & (b) – Avadel Pharmaceuticals plc","datePublished":"2025-11-05T23:19:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/"},"wordCount":916,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTUwNyM3MjQ2MzI3IzIwOTA5NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/","name":"FORM 8.1(a) & (b) - Avadel Pharmaceuticals plc - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTUwNyM3MjQ2MzI3IzIwOTA5NTM=","datePublished":"2025-11-05T23:19:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTUwNyM3MjQ2MzI3IzIwOTA5NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTUwNyM3MjQ2MzI3IzIwOTA5NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/form-8-1a-b-avadel-pharmaceuticals-plc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"FORM 8.1(a) & (b) – Avadel Pharmaceuticals plc"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/906209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=906209"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/906209\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=906209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=906209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=906209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}